NASDAQ:CDXCChromadex Stock Price, Forecast & News

Chromadex's stock was trading at $3.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CDXC shares have increased by 23.1% and is now trading at $4.53. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chromadex.

Chromadex is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Chromadex.

Chromadex Corp (NASDAQ:CDXC) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.01. The firm had revenue of $14.35 million for the quarter, compared to analyst estimates of $13.76 million. Chromadex had a negative return on equity of 132.48% and a negative net margin of 58.73%. View Chromadex's earnings history.

3 brokers have issued 12-month target prices for Chromadex's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Chromadex's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 32.5% from the stock's current price. View analysts' price targets for Chromadex.

Headlines about CDXC stock have trended negative on Sunday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chromadex earned a daily sentiment score of -2.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days. View the latest news about Chromadex.

Chromadex saw a drop in short interest in June. As of June 15th, there was short interest totaling 2,290,000 shares, a drop of 7.7% from the May 31st total of 2,480,000 shares. Based on an average trading volume of 562,000 shares, the short-interest ratio is currently 4.1 days. Currently, 6.4% of the company's shares are short sold. View Chromadex's Current Options Chain.

Some companies that are related to Chromadex include Tilray (TLRY), Canopy Rivers (RIV), Mediwound (MDWD), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), True Drinks (TRUU), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO) and Beleave (BE). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chromadex investors own include Heron Therapeutics (HRTX), Tilray (TLRY), TransEnterix (TRXC), Athersys (ATHX), Glu Mobile (GLUU), Axsome Therapeutics (AXSM), CELYAD SA/ADR (CYAD), Mesoblast (MESO), Sorrento Therapeutics (SRNE) and FuelCell Energy (FCEL).

Chromadex trades on the NASDAQ under the ticker symbol "CDXC."

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDXC stock can currently be purchased for approximately $4.53.

Chromadex has a market capitalization of $278.50 million and generates $46.29 million in revenue each year. The company earns $-32,150,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chromadex employs 100 workers across the globe.

The official website for Chromadex is www.chromadex.com.

Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected]